Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann W Morgan

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2026
Higher complement C4 gene copy number constitutes a shared genetic risk factor for giant cell arteritis and IgA vasculitisLaura Martínez-Gutiérrez, Gonzalo Borrego-Yaniz, José Hernández-Rodríguez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Arthritis Research & Therapy|July 19, 2006
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritisAnn W Morgan, Jim I Robinson, Jennifer H Barrett, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Hemasphere|July 8, 2026
Inflammatory signatures in the spectrum of myeloid diseasesAlice Ibbotson, Simon Crouch, Jacqueline Ferrari, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid ArthritisDarren Plant, Amy Webster, Nisha Nair, et al.
Pharmacogenomics|March 15, 2014
MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysisMichael D Morgan, Nashwa Al-Shaarawy, Steve Martin, et al.
The Journal of Infection|September 6, 2024
Plasma MERTK is causally associated with infection mortalityMichael Drozd, Fergus Hamilton, Chew W Cheng, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2026
Higher complement C4 gene copy number constitutes a shared genetic risk factor for giant cell arteritis and IgA vasculitisLaura Martínez-Gutiérrez, Gonzalo Borrego-Yaniz, José Hernández-Rodríguez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Arthritis Research & Therapy|July 19, 2006
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritisAnn W Morgan, Jim I Robinson, Jennifer H Barrett, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Hemasphere|July 8, 2026
Inflammatory signatures in the spectrum of myeloid diseasesAlice Ibbotson, Simon Crouch, Jacqueline Ferrari, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid ArthritisDarren Plant, Amy Webster, Nisha Nair, et al.
Pharmacogenomics|March 15, 2014
MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysisMichael D Morgan, Nashwa Al-Shaarawy, Steve Martin, et al.
The Journal of Infection|September 6, 2024
Plasma MERTK is causally associated with infection mortalityMichael Drozd, Fergus Hamilton, Chew W Cheng, et al.
Pageof 14